GLP-1 receptor agonist
Exenatide
Answer
Exenatide is authorised or registered in the US, the UK, Canada, Brazil and Turkey: 5 of the 10 registers read. Highest trial phase: Phase 2. It has 383 registered trials, 18 of them running. Brand names on the FDA label register: Byetta and Exenatide.
RegulatorTrial register10 regulators' registers, read 2026-09-03 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
383 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 118 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 2026 is not complete. 292 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Withdrawn | EMA, ema | 2026-10-03 |
| United Kingdom | Authorised | MHRA, uk-mhra | 2026-09-03 |
| Canada | Authorised | Health Canada, ca-dpd | 2026-09-03 |
| Australia | Status unknown | TGA, au-artg | not read |
| Switzerland | Not on the register | Swissmedic, ch-swissmedic | 2026-09-03 |
| Brazil | Registado | ANVISA, br-anvisa | 2026-09-03 |
| Serbia | Not on the register | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Not on the register | HSA, sg-hsa | 2026-09-03 |
| Turkey | Ruhsatli | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
Side effects
Trial registerCHANGE ALERTS
Get an email when this changes
One email when the status of Exenatide changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 383 trials
| NCT05663515 | A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide a currently recruiting participants · register updated 2026-09-24 |
|---|---|
| NCT06725693 | Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease currently recruiting participants · register updated 2026-09-08 |
| NCT05220917 | Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study running, but no longer enrolling · register updated 2026-08-13 |
| NCT07702461 | Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists currently recruiting participants · register updated 2026-07-24 |
| NCT07497399 | Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis currently recruiting participants · register updated 2026-07-17 |
| NCT05356104 | GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) currently recruiting participants · register updated 2026-06-05 |
| NCT02860923 | Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy completed · register updated 2026-05-22 |
| NCT02042664 | Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG completed · register updated 2026-05-07 |
| NCT04232969 | Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease completed · register updated 2026-05-06 |
| NCT05482789 | Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes currently recruiting participants · register updated 2026-04-20 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.